Results 171 to 180 of about 1,680,438 (318)

Optimizing Drug Therapy in ECMO-Supported Critically Ill Adults: A Narrative Review and Clinical Guide. [PDF]

Pharmacy (Basel)
Rocha-Romero A, Chaverri-Fernandez JM, Chaves-Fernández F, Zavaleta-Monestel E.   +3 more
europepmc   +1 more source

Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine [PDF]

Elena Cojocaru, Ovidiu Rusalim Petriș, Cristian Cojocaru   +2 more
openalex   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions. [PDF]

Eur J Hum Genet
Omran S, Gan SH, Teoh SL.
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Anticancer drug therapy for anaplastic thyroid cancer. [PDF]

Eur Thyroid J
Kiyota N, Koyama T, Sugitani I.
europepmc   +1 more source

Do general practitioners and community pharmacists want information on the reasons for drug therapy changes implemented by secondary care?

, 1997
Angela Munday, B E Kelly, J. W. E. Forrester, Angela Timoney, E. M. McGovern   +4 more
openalex   +1 more source

Functionalized Nanoparticles for Drug Delivery, One- and Two-photon Photodynamic Therapy as a Promising Treatment of Retinoblastoma

, 2013
Audrey Gallud
openalex   +2 more sources

Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring [PDF]

, 2011
Andrea Kuemmerle, Alex Dodoo, Sten Olsson, Jan Van Erps, C. Burri, Paul S Lalvani   +5 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source